Asbestos lung cancer refers to lung carcinomas where exposure to asbestos is a major cause of the disease. People with a history of asbestos exposure are several times more likely to develop lung cancer. Smoking significantly increases this risk.
Lung cancer is the second-most-common type of cancer in men and women and the leading cause of cancer death in the nation.
According to American Cancer Society estimates, there will be more than 228,150 cases of lung cancer diagnosed in 2019. Approximately 142,670 Americans will die from lung cancer this year.
About 80 percent of lung cancer deaths are attributed to smoking. Exposure to asbestos only accounts for roughly 4 percent of all lung cancer cases.
However, asbestos-related lung cancer is much more common than pleural mesothelioma, a rare cancer that forms on the thin lining surrounding the lungs.
Data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program estimates 6,000 Americans die of asbestos-related lung cancer each year. All forms of malignant mesothelioma kill roughly 2,500 Americans each year, according to the Centers for Disease Control and Prevention.
The National Cancer Institute confirmed asbestos exposure as a cause of lung cancer in 1942.
When microscopic asbestos fibers are inhaled, they can become stuck in the lung tissue. Over time — typically 15 to 35 years — these fibers cause genetic and cellular damage that can lead to cancer.
Several factors affect whether a person will develop asbestos-related lung cancer, including:
The symptoms of asbestos-related lung cancer are the same as in lung cancer cases caused by smoking.
Treatment options for asbestos-related lung cancer include surgery, chemotherapy, radiation therapy and emerging treatments such as immunotherapy.
Patients diagnosed in the earlier stages typically have more treatment options available and respond better to treatment.
Unlike pleural mesothelioma, there are several immunotherapy drugs approved by the U.S. Food & Drug Administration to treat non-small cell lung cancer (NSCLC) — which represents about 85 percent of all lung cancer cases.
Many asbestos-related lung cancer patients can access these immunotherapies and other treatments through clinical trials and compassionate-use programs.
People who have a past history of occupational asbestos exposure are more at risk of developing asbestos-related lung cancer. This risk is much greater if the person has a heavy smoking history.
A 2017 study published in Molecular and Clinical Oncology analyzed 147 male patients with asbestos-related lung cancer.
The most common work histories among patients in the study included:
The most common types of jobs were:
Ex-smokers represented 79.5 percent of patients of the cohort, followed by smokers (10.3 percent) and nonsmokers (5.5 percent).
All patients in the study had a median duration of asbestos exposure of 28.3 years and a mean latency period of 10.5 years.
Former workers of these occupations are also at risk for other asbestos-related diseases such as asbestosis and pleural scarring.
6 Cited Article Sources
Sponsored by The Peterson Firm, 1050 30th Street NW, Washington, DC 20007 © 2019 PleuralMesothelioma.com